Quantitative Investment Management, LLC Biomarin Pharmaceutical Inc Transaction History

Quantitative Investment Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$76.22 - $98.51 $881,484 - $1.14 Million	11,565 New	11,565 $1.12 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $1.53 Million - $2.05 Million	18,854 Added 437.55%	23,163 $2.4 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $354,027 - $417,714	4,309 New	4,309 $365,000
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $434,240 - $541,865	-5,846 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $419,275 - $534,733	5,846 New	5,846 $516,000
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $1.65 Million - $1.89 Million	-22,070 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $1.67 Million - $1.87 Million	22,070 New	22,070 $1.84 Million
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $1.93 Million - $2.34 Million	-25,775 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $1.87 Million - $2.32 Million	25,775 New	25,775 $2.26 Million
Q4 2017 Feb 14, 2018	SELL	$80.76 - $95.13 $1.28 Million - $1.5 Million	-15,800 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$80.6 - $94.95 $1.27 Million - $1.5 Million	15,800	15,800 $1.47 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Quantitative Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Quantitative Investment Management, LLC with notifications on news.